Mr. Market is currently offering STERIS plc at $212.82.
The business passes 4 of 7 of Graham's defensive criteria — adequate but not exceptional.
At $212.82, the stock trades at a 120% premium to its Graham Number of $96.92. Graham would consider this price speculative.
There is no margin of safety at the current price. Graham would advise patience and waiting for a better entry point.
Negative NCAV — liabilities exceed current assets. Common in capital-return businesses (buybacks, debt-funded dividends) and capital-intensive industries. Not automatically a warning sign..
Conclusion: This stock is better suited for Graham's Enterprising investor — one willing to devote time and skill to security selection.
STERIS plc provides infection prevention products and services worldwide. It operates in three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Gross Profit % | 44.0% ▲ | 43.2% | 43.7% | 44.6% |
| Operating Margin % | 17.6% ▲ | 16.8% | 17.5% | 11.3% |
| Net Income % | 11.3% ▲ | 7.4% | 2.4% | 5.8% |
| Diluted EPS | 6.20 ▲ | 3.81 | 1.07 | 2.48 |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | $10.1B | $11.1B | $10.8B | $11.4B |
| Total Debt | $2.2B ↓ | $3.4B | $3.2B | $3.3B |
| Working Capital | $979M ▼ | $1.9B | $1.1B | $957M |
| Years to Pay Debt | 3.58 | 8.94 | 30.35 | 13.45 |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Free Cash Flow | $778M ▲ | $613M | $395M | $397M |
| Owner Earnings | $1.5B | $1.3B | $1.0B | $1.1B |
| CapEx % of Net Income | 60.2% | 95.3% | 338.2% | 117.9% |
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Capital Expenditure % of Net Income | 60.2% | 95.3% | 338.2% | 117.9% |
| Repurchase of Capital Stock | -$211M | -$12M | -$309M | -$56M |
| Free Cash Flow | $778M ▲ | $613M ▲ | $395M ▼ | $397M • |
| Warren's Owner Earnings | $1.5B | $1.3B | $1.0B | $1.1B |
| Company | Price | Market Cap | P/E | Gross Margin | Net Margin | Revenue |
|---|---|---|---|---|---|---|
| STE | $212.82 | $20.9B | 29.72 | 44.0% | 11.3% | $5.5B |
| MDT Medtronic plc. |
$78.57 | $100.9B | 21.9 | 65.2% | 13.0% | $35.5B |
| ABT Abbott Laboratories |
$87.58 | $152.5B | 24.5 | 56.5% | 13.9% | $45.1B |
| SYK Stryker Corporation |
$292.65 | $112.1B | 34.8 | 64.7% | 13.2% | $25.3B |
| BSX Boston Scientific Corporation |
$57.17 | $85.0B | 23.9 | 68.9% | 17.3% | $20.6B |
| EW Edwards Lifesciences Corporatio |
$83.38 | $48.1B | 45.1 | 77.9% | 17.4% | $6.3B |
| Institution | % Owned | Shares |
|---|---|---|
| Vanguard Group Inc | 12.53% | 12,286,535 |
| Blackrock Inc. | 9.22% | 9,041,433 |
| State Street Corporation | 4.71% | 4,614,840 |
| Massachusetts Financial Services Co. | 4.30% | 4,218,307 |
| Morgan Stanley | 3.92% | 3,839,818 |
| Geode Capital Management, LLC | 2.57% | 2,523,620 |
| Orbis Allan Gray Ltd | 2.29% | 2,249,511 |
| Generation Investment Management LLP | 2.13% | 2,088,483 |
STERIS plc (STE) fundamental analysis — Overall grade C based on profitability, financial health, valuation and cash flow. Graham's Fair Value: $96.92. Margin of safety: 0%. Gross profit margin: 44.0%. Operating margin: 17.6%. Net margin: 11.3%. Market cap: $20.9B. Sector: Healthcare. Industry: Medical Devices. Analysis powered by 360investing — free fundamental stock analysis based on Benjamin Graham and Warren Buffett principles.
Disclaimer: 360investing is provided for informational and educational purposes only and does not constitute financial, investment, legal, or tax advice. All data is sourced from public third-party providers and may be delayed, inaccurate, or incomplete. Past performance is not indicative of future results. Analysis, scores, and valuations are algorithmic and do not represent professional investment recommendations. Always conduct your own due diligence and consult a qualified financial adviser before making any investment decision. Use of this tool constitutes acceptance that 360investing and its operators bear no liability for decisions made based on information presented here.